NovaBridge Doses First Patient in Global, Randomized Phase 2 Study of Givastomig Combined with Immunochemotherapy in Patients with 1L Metastatic Gastric Cancer
Rhea-AI Summary
NovaBridge (Nasdaq: NBP) dosed the first patient in a global, randomized Phase 2 study testing givastomig (CLDN18.2 x 4-1BB) plus nivolumab and mFOLFOX6 in 1L HER2-negative metastatic gastric cancer.
Phase 2 uses 8 mg/kg and 12 mg/kg dose arms, follows Phase 1b showing ORR 75% and mPFS 16.9 months, and targets top-line results in 2027. The company cites a $12 billion market opportunity by 2030.
Positive
- Phase 1b efficacy: ORR 75%
- Median progression-free survival 16.9 months
- Top-line Phase 2 expected in 2027
- Market opportunity projected at $12 billion by 2030
Negative
- No randomized Phase 2 efficacy confirmation yet
- Phase 2 results expected in 2027, creating multi-year outcome timeline
News Market Reaction – NBP
On the day this news was published, NBP gained 0.31%, reflecting a mild positive market reaction. This price movement added approximately $1M to the company's valuation, bringing the market cap to $371M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Previous Clinical trial Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 10 | Clinical data update | Positive | +1.7% | Phase 1 ragistomig dose‑expansion data showing efficacy and safety profile. |
| Dec 03 | Clinical data preview | Positive | +4.9% | Announcement of expanded ragistomig Phase 1 data presentation at ESMO‑IO. |
Tagged clinical‑trial announcements have historically produced modest positive price reactions for NBP.
Over the last several months, NovaBridge has highlighted progressing bispecific antibody programs, with clinical‑trial news on ragistomig in December 2025 generating positive but measured moves of 1.74% and 4.94%. Separately, updated Phase 1b givastomig data and insider share‑purchase intentions reinforced management’s focus on first‑line metastatic gastric cancer. Today’s Phase 2 givastomig initiation builds directly on those earlier proof‑of‑concept results, extending the company’s oncology platform strategy into a larger, randomized setting while the stock remains near its 52‑week low.
Historical Comparison
In the past 6 months, NBP’s clinical‑trial headlines produced an average move of 3.34%. Today’s Phase 2 givastomig initiation fits the pattern of incremental, data‑driven oncology updates.
Clinical updates have advanced from ragistomig Phase 1 dose‑optimization towards mid‑stage development, while givastomig now moves from strong Phase 1b results into a global randomized Phase 2 in first‑line metastatic gastric cancer.
Market Pulse Summary
This announcement advances givastomig into a global randomized Phase 2 study for 1L metastatic gastric cancer, leveraging Phase 1b data with ORR of 75%, mPFS of 16.9 months and six‑month PFS of 82%. The program targets a gastric cancer market the company pegs at $12 billion by 2030, with top‑line Phase 2 results expected in 2027. Investors may track enrollment progress, safety signals and consistency of efficacy across CLDN18.2 and PD‑L1 expression levels.
Key Terms
phase 2 medical
bispecific antibody medical
cldn18.2 medical
4-1bb medical
immunochemotherapy medical
objective response rate medical
median progression free survival medical
pd-l1 medical
AI-generated analysis. Not financial advice.
- Global, randomized Phase 2 study to evaluate the addition of givastomig, a CLDN18.2 x 4-1BB bispecific antibody (8 mg/kg and 12 mg/kg) to standard of care immunochemotherapy in patients with first line (1L) metastatic gastric cancer
- Major milestone builds on positive Phase 1b combination data demonstrating that givastomig produced, best-in-class potential efficacy in 1L HER2-negative, metastatic gastric cancer patients in combination with nivolumab and chemotherapy (mFOLFOX6)
- Phase 1b results showed that patients treated with givastomig experienced an objective response rate (ORR) of
75% , median progression free survival (mPFS) of 16.9 months and82% six-month landmark PFS - Gastric cancer represents a
$12 billion market opportunity by 2030 - Top line results from the Phase 2 study are expected in 2027
ROCKVILLE, Md., Feb. 17, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative medicines, today announced enrollment of the first patient in the global Phase 2 randomized combination study evaluating givastomig, a Claudin 18.2 (CLDN18.2) x 4-1BB bispecific antibody, in combination with nivolumab and chemotherapy (mFOLFOX6) in patients with HER2-negative, 1L metastatic gastric cancer. Positive Phase 1b data position givastomig to be a potential best-in-class CLDN18.2-directed therapy for gastric cancer with a projected
“We are pleased to be advancing givastomig one step closer towards commercialization, with the initiation of the global randomized Phase 2 study. The study builds on the compelling Phase 1b givastomig results, showing robust efficacy and favorable overall tolerability, and demonstrating a potential marked improvement relative to historical benchmarks for the standard of care. The Phase 2 study is designed to confirm these results in a broader setting and validate givastomig as a potential best in class therapy for 1L metastatic gastric cancer, with the potential for broad utilization across CLDN18.2 levels in PD-L1 positive patients,” said Phillip Dennis, MD, PhD, Chief Medical Officer of NovaBridge. “We expect to present results from this study in 2027. In addition, we expect to present updated results from the Phase 1b dose expansion study in the second half of this year.”
“We continue to be encouraged by givastomig’s high response rate across a wide range of Claudin 18.2 and PD-L1 expression levels. The depth and duration of responses achieved with combination therapy coupled with the tolerability enabled the swift enrollment in the Phase 1b study and provides a strong basis to move to the next stage of development,” said Samuel J. Klempner, MD, Associate Professor of Medicine at Mass General Brigham Cancer Institute. “We are hopeful that, with continued positive clinical results, givastomig will ultimately become a standard of care for gastric and esophageal cancer.”
“Initiation of the Phase 2 study marks a pivotal moment for NovaBridge as we transition to a mid-stage clinical Company. Compelling Phase 1b efficacy and safety data validate givastomig’s potential as a premier CLDN18.2-directed therapy for gastric cancer and beyond. The strong and durable response data underscore our conviction in givastomig’s significant commercial potential,” said Sean Fu, PhD, MBA, Chief Executive Officer of NovaBridge. “We remain focused on developing novel, differentiated therapies that can transform the treatment of patients worldwide and believe that givastomig will be a cornerstone of our future growth.”
About the Givastomig Phase 1b Dose Escalation and Expansion Combination Study in 1L Gastric Cancer
The Phase 1b dose expansion data (per the January 6, 2026 press release and corporate presentation) showed that givastomig, dosed at 8 mg/kg every two weeks (Q2W) and 12 mg/kg Q2W, produced:
- Robust efficacy, with
75% ORR (77% ORR observed at 8 mg/kg,73% ORR observed at 12 mg/kg, n=52 evaluable) - Responses observed across a wide range of PD-L1 and CLDN18.2 expression levels
- Durable responses with 16.9-month mPFS and an
82% 6-month landmark PFS rate (n=53 evaluable) - With good overall tolerability in combination with immunochemotherapy, without dose dependent toxicity
Detailed Phase 1b expansion data are expected to be presented at a major medical conference in H2 2026
About the Global, Randomized Phase 2 Study of Givastomig in the Setting of 1L Gastric Cancer
The Phase 2 global, randomized study is evaluating the safety and efficacy of givastomig, used in combination with nivolumab and mFOLFOX6, as 1L therapy in patients with CLDN18.2-positive gastric cancer, including gastroesophageal cancer (GEC), gastroesophageal junction cancer (GEJ), gastroesophageal adenocarcinoma (GEA), with CLDN18.2 levels of ≥1+ immunohistochemistry (IHC) intensity on ≥
Sources:
- Markets include U.S., five E.U. countries, and Japan by 2030 for potential sales based on Data Monitor Biomed Tracker
About Givastomig
Givastomig (TJ033721 / ABL111) is a bispecific antibody targeting Claudin 18.2 (CLDN18.2)-positive tumor cells. It conditionally activates T cells through the 4-1BB signaling pathway in the tumor microenvironment where CLDN18.2 is expressed. Givastomig is being developed for potential treatment of gastric cancer and other Claudin 18.2-positive gastrointestinal malignancies. In Phase 1 trials, givastomig has shown promising anti-tumor activity attributable to a potential synergistic effect of proximal interaction between CLDN18.2 on tumor cells and 4-1BB on T cells in the tumor microenvironment, while minimizing toxicities commonly seen with other 4-1BB agents.
Givastomig is being jointly developed through a global partnership with ABL Bio, in which NovaBridge is the lead party and shares worldwide rights, excluding Greater China and South Korea, equally with ABL Bio.
About NovaBridge
NovaBridge is a global biotechnology platform company committed to accelerating access to innovative medicines. The Company combines deep business development expertise with agile translational clinical development to identify, accelerate, and advance breakthrough assets. By bridging science, strategy, and execution, NovaBridge enables transformative therapies to progress rapidly from discovery toward patients in need.
The Company’s differentiated pipeline is led by givastomig, a potential best-in-class, Claudin 18.2 x 4-1BB bispecific antibody, and VIS-101, a second-in-class, potentially best-in-class bifunctional biologic, targeting VEGF-A and ANG2.
Givastomig conditionally activates T cells via the 4-1BB signaling pathway in the tumor microenvironment where Claudin 18.2 is expressed. Givastomig is being developed to treat Claudin 18.2-positive gastric cancer and other gastrointestinal malignancies. The product candidate is being evaluated in a global, randomized Phase 2 study, following the recent announcement of positive topline results from a Phase 1b, multi-center, open label study in first line gastric cancer. The Company is also collaborating with its partner, ABL Bio, for the development of ragistomig, a bispecific antibody integrating PD-L1 as a tumor engager and 4-1BB as a conditional T cell activator, in solid tumors. Additionally, NovaBridge owns worldwide rights outside of China to uliledlimab, an anti-CD73 antibody that targets adenosine-driven immunosuppression in cancer.
VIS-101 targets VEGF-A and ANG-2 to provide more potent and durable treatment benefits for patients with wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). VIS-101 is currently completing a randomized, dose-ranging Phase 2a study for wet AMD. NovaBridge is the majority shareholder of Visara, and Visara controls global rights to VIS-101, outside of Greater China and certain countries in Asia.
For more information, please visit www.novabridge.com and follow us on LinkedIn.
Forward Looking Statements
This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will”, “expects”, “believes”, “designed to”, “anticipates”, “future”, “intends”, “plans”, “potential”, “estimates”, “confident”, and similar terms or the negative thereof. NovaBridge may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the SEC), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about the Company’s beliefs and expectations, are forward-looking statements. Forward-looking statements in this press release include, without limitation, statements regarding: the strategy, clinical development, plans, results, safety and efficacy of givastomig and VIS-101 and its other drug candidates; the strategic and clinical development of NovaBridge’s drug candidates, including givastomig, ragistomig, uliledlimab, and VIS-101; anticipated clinical milestones and results, and related timing. Forward-looking statements involve inherent risks and uncertainties that may cause actual results to differ materially from those contained in these forward-looking statements, including but not limited to the following: the Company’s ability to demonstrate the safety and efficacy of its drug candidates; the Company’s ability to enroll patients and complete clinical studies on the timelines contemplated; the clinical results for its drug candidates, which may or may not support further development or New Drug Application/Biologics License Application (NDA/BLA) approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of the Company’s drug candidates; the Company’s ability to achieve commercial success for its drug candidates, if approved; the Company’s ability to obtain and maintain protection of intellectual property for its technology and drugs; the Company’s reliance on third parties to conduct drug development, manufacturing and other services; the Company’s limited operating history and the Company’s ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates; and those risks more fully discussed in the “Risk Factors” section in the Company’s annual report on Form 20-F filed with the SEC on April 3, 2025 as well as the discussions of potential risks, uncertainties, and other important factors in the Company’s subsequent filings with the SEC. All forward-looking statements are based on information currently available to the Company. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law.
NovaBridge Investor & Media Contacts
PJ Kelleher
LifeSci Advisors
+1-617-430-7579
pkelleher@lifesciadvisors.com
NovaBridge Biosciences
+1-240-745-6330
IR@novabridge.com
FAQ
What did NovaBridge (NBP) announce about givastomig on February 17, 2026?
What were the Phase 1b clinical results for givastomig reported by NovaBridge (NBP)?
When does NovaBridge expect top-line results from thegivastomig Phase 2 study (NBP)?
What patient population is NovaBridge targeting in the givastomig Phase 2 (NBP) trial?
How large is the market opportunity NovaBridge cites for givastomig (NBP)?
